Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of trimetazidine on ventricular remodeling, serum Cys C and ET-1 levels in patients with chronic heart failure

Xiaoyan Wu¹, Wenzhong Chen² , Huiming Han³

¹Department of Cardiovascular Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, China; ²Department of Cardiovascular Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China; ³Department of Clinical Laboratory, Haikou Maternal and Child Health Hospital, Haikou, China.

For correspondence:- Wenzhong Chen Email: 417702577@qq.com Tel:+8613427542142

Accepted: 30 July 2023 Published: 31 August 2023

Citation: Wu X, Chen W, Han H. Effect of trimetazidine on ventricular remodeling, serum Cys C and ET-1 levels in patients with chronic heart failure. Trop J Pharm Res 2023; 22(8):1713-1718 doi: 10.4314/tjpr.v22i8.24

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the effect of trimetazidine on ventricular remodeling and serum levels of cystatin C and endothelin-1 in patients with chronic heart failure (CHF).

Methods: A total of 96 patients with CHF were randomly divided into two groups, given either conventional treatment (control group) or conventional treatment plus trimetazidine (study group) for 6 months. Clinical efficacy was compared between the two groups. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured using cardiac echocardiography before and after treatment. Patients were recorded at 6 MVT before and after treatment. An automatic biochemical analyzer was used to assay serum Cys C levels before and after treatment. Serum levels of ET-1, galactose agglutinin-3 (GAL-3), brain natriuretic peptide (BNP) and heart natriuretic peptide (ANP) were determined by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Incidence of adverse events in CHF patients was compared between groups.

Results: Study group had a significantly higher level of treatment effectiveness (91.67 %) and better improvement in left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter than control group (p < 0.05). Serum levels of serum cystatin C, endothelin-1 and other biomarkers were also significantly lower (p < 0.05) in study group. Re-hospitalization rate was also lower in study group.

Conclusion: Trimetazidine exerts a therapeutic effect on CHF patients, effectively improves cardiac function and reduces the rate of re-hospitalization.

Keywords: Chronic heart failure, Trimetazidine, Endothelin-1, Cystatin C